References
- Carmina E, Lobo RA. Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. J Clin Endocrinol Metab 1999;84:1897–9
- Azziz R, Woods KS, Reyna R, et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004;89:2745–9
- Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet 2007;370:685–97
- Vrbíková J, Grimmichová T, Dvoráková K, et al. Family history of diabetes mellitus determines insulin sensitivity and beta cell function in polycystic ovary syndrome. Physiol Res 2008;57:547–53
- Palmert MR, Gordon CM, Kartashov AI, et al. Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome. J Clin Endocrinol Metab 2002;87:1017–23
- Venkatesan AM, Dunaif A, Corbould A. Insulin resistance in polycystic ovary syndrome: progress and paradoxes. Recent Prog Horm Res 2001;56:295–308
- İvier JE, Rivier CL. Corticotropin-releasing factor peptide antagonists: design, characterization and potential clinical relevance. Front Neuroendocrinol 2014;35:161–70
- Nozu T, Tsuchiya Y, Kumei S, et al. Peripheral corticotropin-releasing factor (CRF) induces stimulation of gastric contractions in freely moving conscious rats: role of CRF receptor types 1 and 2. Neurogastroenterol Motil 2013;25:190–7
- Bale TL, Hoshijima M, Gu Y, et al. The cardiovascular physiologic actions of urocortin II: acute effects in murine heart failure. Proc Natl Acad Sci USA 2004;101:3697–702
- Kuperman Y, Chen A. Urocortins: emerging metabolic and energy homeostasis perspectives. Trends Endocrinol Metab 2008;19:122–9
- Gravanis A, Margioris AN. The corticotropin-releasing factor (CRF) family of neuropeptides in inflammation: potential therapeutic applications. Curr Med Chem 2005;12:1503–12
- Martinez V, Wang L, Million M, et al. Urocortins and the regulation of gastrointestinal motor function and visceral pain. Peptides 2004;25:1733–44
- Yamauchi N, Otagiri A, Nemoto T, et al. Distribution of urocortin 2 in various tissues of the rat. J Neuroendocrinol 2005;17:656–63
- Hsu SY, Hsueh AJ. Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor. Nat Med 2001;7:605–11
- Li C, Chen P, Vaughan J, et al. Urocortin 3 regulates glucose-stimulated insulin secretion and energy homeostasis. Proc Natl Acad Sci USA 2007;104:4206–11
- Chen A, Brar B, Choi CS, et al. Urocortin 2 modulates glucose utilization and insulin sensitivity in skeletal muscle. Proc Natl Acad Sci USA 2006;103:16580–5
- Spyroglou A, Riester A, Mueller-Peltzer K, et al. Adrenal and ovarian phenotype of a tissue-specific urocortin 2 overexpressing mouse model. Endocrinology 2015;156:2646–56
- Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19–25
- Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21:1440–7
- Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–19
- Chao H, Li H, Grande R, et al. Involvement of mTOR in type 2 CRF receptor ınhibition of ınsulin signaling in muscle cells. Mol Endocrinol 2015;29:831–41
- Ikeda K, Baba T, Noguchi H, et al. Excessive androgen exposure in female-to-male transsexual persons of reproductive age induces hyperplasia of the ovarian cortex and stroma but not polycystic ovary morphology. Hum Reprod 2013;28:453–61
- Abbott DH, Barnett DK, Bruns CM, Dumesic DA. Androgen excess fetal programming of female reproduction: a developmental aetiology for polycystic ovary syndrome? Hum Reprod Update 2005;11:357–74
- Vendola KA, Zhou J, Adesanya OO, et al. Androgens stimulate early stages of follicular growth in the primate ovary. J Clin Invest 1998;101:2622–9
- Gougeon A. Regulation of ovarian follicular development in primates: facts and hypotheses. Endocr Rev 1996;17:121–55
- Nemoto T, Yamauchi N, Shibasaki T. Novel action of pituitary urocortin 2 in the regulation of expression and secretion of gonadotropins. J Endocrinol 2009;201:105–14
- Mastorakos G, Webster EL, Chrousos GP. Corticotropin-releasing hormone and its receptors in the ovary: physiological implications. Ann NY Acad Sci 1993;687:20–8
- Temur M, Yilmaz Ö, Aksun S, et al. Increased circulating urocortin-3 levels is associated with polycystic ovary syndrome. Gynecol Endocrinol 2016;32:218–22